Dendritic cell therapy for Type 1 diabetes suppression

Immunotherapy

Volumn 4, Issue 10, 2012, Pages 1063-1074

  Giannoukakis, Nick ^a   Trucco, Massimo ^a  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

autoimmunity; cell therapy; cell vaccine; clinical trial; dendritic cells; immunotherapy; tolerance; Type 1 diabetes

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; B7 ANTIGEN; CD40 ANTIGEN; CD86 ANTIGEN; GLUTAMATE DECARBOXYLASE 65; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 4; PROSTATE SPECIFIC ANTIGEN; TRANSFORMING GROWTH FACTOR BETA;

AMINO ACID ANALYSIS; ANTIGEN SPECIFICITY; APOPTOSIS; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL POPULATION; CROSS PRESENTATION; CYTOKINE PRODUCTION; DENDRITIC CELL; DIABETIC PATIENT; GRAFT SURVIVAL; HUMAN; IMMUNOTHERAPY; INSULIN DEPENDENT DIABETES MELLITUS; LYMPHOCYTE PROLIFERATION; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHAGOCYTOSIS; PHENOTYPE; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SIGNAL TRANSDUCTION;

ANIMALS; CLINICAL TRIALS, PHASE I AS TOPIC; DENDRITIC CELLS; DIABETES MELLITUS, TYPE 1; HUMANS; IMMUNE TOLERANCE; TISSUE THERAPY;

EID: 84869165311     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.12.76     Document Type: Review

References (130)

1. Gianani R, Eisenbarth GS. The stages of Type 1A diabetes: 2005. Immunol. Rev. 204, 232-249 (2005).
2. Di Lorenzo TP, Peakman M, Roep BO. Translational mini-review series on Type 1 diabetes: Systematic analysis of T cell epitopes in autoimmune diabetes. Clin. Exp. Immunol. 148(1), 1-16 (2007).
3. Feutren G, Papoz L, Assan R et al. Cyclosporin increases the rate and length of remissions in insulin-dependent diabetes of recent onset. Results of a multicentre double-blind trial. Lancet 2(8499), 119-124 (1986).
4. Bresson D, von Herrath M. Immunotherapy for the prevention and treatment of Type 1 diabetes: optimizing the path from bench to bedside. Diabetes Care 32(10), 1753-1768 (2009).
5. Rewers M, Gottlieb P. Immunotherapy for the prevention and treatment of Type 1 diabetes: human trials and a look into the future. Diabetes Care 32(10), 1769-1782 (2009).
6. Skyler JS, Ricordi C. Stopping Type 1 diabetes: Attempts to prevent or cure Type 1 diabetes in man. Diabetes 60(1), 1-8 (2011).
7. Clare-Salzler MJ, Brooks J, Chai A, Van Herle K, Anderson C. Prevention of diabetes in nonobese diabetic mice by dendritic cell transfer. J. Clin. Invest. 90(3), 741-748 (1992).
8. Banchereau J, Palucka AK, Dhodapkar M et al. Immune and clinical responses in patients with metastatic melanoma to CD34+ progenitor-derived dendritic cell vaccine. Cancer Res. 61(17), 6451-6458 (2001).
9. De Vries IJ, Lesterhuis WJ, Scharenborg NM et al. Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin. Cancer Res. 9(14), 5091-5100 (2003).
10. Heiser A, Coleman D, Dannull J et al. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J. Clin. Invest. 109(3), 409-417 (2002).
11. Holtl L, Zelle-Rieser C, Gander H et al. Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells. Clin. Cancer Res. 8(11), 3369-3376 (2002).
12. Hsu FJ, Benike C, Fagnoni F et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med. 2(1), 52-58 (1996).
13. Jonuleit H, Giesecke-Tuettenberg A, Tuting T et al. A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. Int. J. Cancer 93(2), 243-251 (2001).
14. Mackensen A Herbst B Chen JL et al. Phase I study in melanoma patients of Vaccine With Peptide-pulsed Dendritic Cells Generated In Vitro From CD34+ Hematopoietic Progenitor Cells. Int. J. Cancer 86(3) 385-392 (2000).
15. Pecher G, Haring A, Kaiser L, Thiel E. Mucin gene (MUC1) transfected dendritic cells as vaccine: Results of a Phase I/II clinical trial. Cancer Immunol. Immunother. 51(11-12), 669-673 (2002).
16. Su Z, Dannull J, Heiser A et al. Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. Cancer Res. 63(9), 2127-2133 (2003).
17. Thurner B, Haendle I, Roder C et al. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J. Exp. Med. 190(11), 1669-1678 (1999).
18. PROVENGE shows few side effects. Hum. Vaccin. 6(7), 524 (2010).
19. Brower V. Approval of provenge seen as first step for cancer treatment vaccines. J. Natl Cancer Inst. 102(15), 1108-1110 (2010).
20. Cheever MA, Higano CS. PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clin. Cancer Res. 17(11), 3520-3526 (2011).
21. Silverman E. Provenge approval means sensitive coverage decisions. Manag. Care 19(9), 31-34 (2010).
22. Thara E, Dorff TB, Pinski JK, Quinn DI. Vaccine therapy with sipuleucel-T (Provenge) for prostate cancer. Maturitas 69(4), 296-303 (2011).
23. Giannoukakis N, Phillips B, Finegold D, Harnaha J, Trucco M. Phase I (safety) study of autologous tolerogenic dendritic cells in Type 1 diabetic patients. Diabetes Care 34(9), 2026-2032 (2011).
24. Phillips B, Giannoukakis N, Trucco M. Dendritic cell-based therapy in Type 1 diabetes mellitus. Expert Rev. Clin. Immunol. 5(3), 325-339 (2009).
25. Feili-Hariri M, Dong X, Alber SM, Watkins SC, Salter RD, Morel PA. Immunotherapy of NOD mice with bone marrow-derived dendritic cells. Diabetes 48(12), 2300-2308 (1999).
26. Feili-Hariri M, Falkner DH, Morel PA. Regulatory Th2 response induced following adoptive transfer of dendritic cells in prediabetic NOD mice. Eur. J. Immunol. 32(7), 2021-2030 (2002).
27. Haase C, Ejrnaes M, Juedes AE, Wolfe T, Markholst H, von Herrath MG. Immunomodulatory dendritic cells require autologous serum to circumvent nonspecific immunosuppressive activity in vivo. Blood 106(13), 4225-4233 (2005).
28. Creusot RJ, Yaghoubi SS, Kodama K et al. Tissue-targeted therapy of autoimmune diabetes using dendritic cells transduced to express IL-4 in NOD mice. Clin. Immunol. 127(2), 176-187 (2008).
29. Perone MJ, Bertera S, Tawadrous ZS et al. Dendritic cells expressing transgenic galectin-1 delay onset of autoimmune diabetes in mice. J. Immunol. 177(8), 5278-5289 (2006).
30. Harnaha J, Machen J, Wright M et al. Interleukin-7 is a survival factor for CD4+CD25+ T-cells and is expressed by diabetessuppressive dendritic cells. Diabetes 55(1), 158-170 (2006).
31. Ma L, Qian S, Liang X et al. Prevention of diabetes in NOD mice by administration of dendritic cells deficient in nuclear transcription factor-kappaB activity. Diabetes 52(8), 1976-1985 (2003).
32. Machen J, Harnaha J, Lakomy R, Styche A, Trucco M, Giannoukakis N. Antisense oligonucleotides down-regulating costimulation confer diabetes-preventive properties to nonobese diabetic mouse dendritic cells. J. Immunol. 173(7), 4331-4341 (2004).
33. Chappert P, Leboeuf M, Rameau P et al. Antigen-driven interactions with dendritic cells and expansion of Foxp3+ regulatory T cells occur in the absence of inflammatory signals. J. Immunol. 180(1), 327-334 (2008).
34. Dipaolo RJ, Brinster C, Davidson TS, Andersson J, Glass D, Shevach EM. Autoantigen-specific TGFbeta-induced Foxp3+regulatory T cells prevent autoimmunity by inhibiting dendritic cells from activating autoreactive T cells. J. Immunol. 179(7), 4685-4693 (2007).
35. Lehner T. Special regulatory T cell review: the resurgence of the concept of contrasuppression in immunoregulation. Immunology 123(1), 40-44 (2008).
36. Onishi Y, Fehervari Z, Yamaguchi T, Sakaguchi S. Foxp3+ natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation. Proc. Natl Acad. Sci. USA 105(29), 10113-10118 (2008).
37. Xia G, He J, Leventhal Jr. Ex vivo-expanded natural CD4+CD25+ regulatory T cells synergize with host T-cell depletion to promote long-term survival of allografts. Am. J. Transplant. 8(2), 298-306 (2008).
38. Creusot RJ, Yaghoubi SS, Chang P et al. Lymphoid-tissue-specific homing of bone-marrow-derived dendritic cells. Blood 113(26), 6638-6647 (2009).
39. Atkinson MA, Leiter EH. The NOD mouse model of Type 1 diabetes: As good as it gets? Nat. Med. 5(6), 601-604 (1999).
40. Tian H, Song G, Xie H, Zhang H, Tuomilehto J, Hu G. Prevalence of diabetes and impaired fasting glucose among 769,792 rural Chinese adults. Diabetes Res. Clin. Pract. 84(3), 273-278 (2009).
41. Herold KC, Gitelman S, Greenbaum C et al. Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb teplizumab preserves insulin production for up to 5 years. Clin. Immunol. 132(2), 166-173 (2009).
42. Kaufman A, Herold KC. Anti-CD3 mAbs for treatment of Type 1 diabetes. Diabetes Metab. Res. Rev. 25(4), 302-306 (2009).
43. Keymeulen B, Walter M, Mathieu C et al. Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset Type 1 diabetic patients depends on their age and baseline residual beta cell mass. Diabetologia 53(4), 614-623 (2010).
44. Schell AM, Granger EL, Koczot F, Fischer MA, Norbury CC. Dendritic cell migration limits the duration of CD8+ T-cell priming to peripheral viral antigen. J. Virol. 84(7), 3586-3594 (2010).
45. Kamphorst AO, Guermonprez P, Dudziak D, Nussenzweig MC. Route of antigen uptake differentially impacts presentation by dendritic cells and activated monocytes. J. Immunol. 185(6), 3426-3435 (2010).
46. Long CM, van Laarhoven HW, Bulte JW, Levitsky HI. Magnetovaccination as a novel method to assess and quantify dendritic cell tumor antigen capture and delivery to lymph nodes. Cancer Res. 69(7), 3180-3187 (2009).
47. Lee HK, Zamora M, Linehan MM et al. Differential roles of migratory and resident DCs in T cell priming after mucosal or skin HSV-1 infection. J. Exp. Med. 206(2), 359-370 (2009).
48. Balic A, Smith KA, Harcus Y, Maizels RM. Dynamics of CD11c+ dendritic cell subsets in lymph nodes draining the site of intestinal nematode infection. Immunol. Lett. 127(1), 68-75 (2009).
49. Abadie V, Bonduelle O, Duffy D, Parizot C, Verrier B, Combadiere B. Original encounter with antigen determines antigen-presenting cell imprinting of the quality of the immune response in mice. PLoS ONE 4(12), e8159 (2009).
50. Allan RS, Waithman J, Bedoui S et al. Migratory dendritic cells transfer antigen to a lymph node-resident dendritic cell population for efficient CTL priming. Immunity 25(1), 153-162 (2006).
51. Divito SJ, Wang Z, Shufesky WJ et al. Endogenous dendritic cells mediate the effects of intravenously injected therapeutic immunosuppressive dendritic cells in transplantation. Blood 116(15), 2694-2705 (2010).
52. Tarbell KV, Yamazaki S, Olson K, Toy P, Steinman RM. CD25+ CD4+ T cells, expanded with dendritic cells presenting a single autoantigenic peptide, suppress autoimmune diabetes. J. Exp. Med. 199(11), 1467-1477 (2004).
53. Tarbell KV, Petit L, Zuo X et al. Dendritic cell-expanded, islet-specific CD4+ CD25+ CD62L+ regulatory T cells restore normoglycemia in diabetic NOD mice. J. Exp. Med. 204(1), 191-201 (2007).
54. Bruder D, Westendorf AM, Hansen W et al. On the edge of autoimmunity: T-cell stimulation by steady-state dendritic cells prevents autoimmune diabetes. Diabetes 54(12), 3395-3401 (2005).
55. Mukhopadhaya A, Hanafusa T, Jarchum I et al. Selective delivery of beta cell antigen to dendritic cells in vivo leads to deletion and tolerance of autoreactive CD8+ T cells in NOD mice. Proc. Natl Acad. Sci. USA 105(17), 6374-6379 (2008).
56. Dilorenzo TP, Serreze DV. The good turned ugly: Immunopathogenic basis for diabetogenic CD8+ T cells in NOD mice. Immunol. Rev. 204, 250-263 (2005).
57. Amrani A, Verdaguer J, Serra P, Tafuro S, Tan R, Santamaria P. Progression of autoimmune diabetes driven by avidity maturation of a T-cell population. Nature 406(6797), 739-742 (2000).
58. Han B, Serra P, Amrani A et al. Prevention of diabetes by manipulation of anti-IGRP autoimmunity: high efficiency of a lowaffinity peptide. Nat. Med. 11(6), 645-652 (2005).
59. Hawiger D, Inaba K, Dorsett Y et al. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J. Exp. Med. 194(6), 769-779 (2001).
60. Bonifaz L, Bonnyay D, Mahnke K, Rivera M, Nussenzweig MC, Steinman RM. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance. J. Exp. Med. 196(12), 1627-1638 (2002).
61. Kretschmer K, Apostolou I, Hawiger D, Khazaie K, Nussenzweig MC, von Boehmer H. Inducing and expanding regulatory T cell populations by foreign antigen. Nat. Immunol. 6(12), 1219-1227 (2005).
62. Steinman RM, Hawiger D, Liu K et al. Dendritic cell function in vivo during the steady state: A role in peripheral tolerance. Ann. NY Acad. Sci. 987, 15-25 (2003).
63. Dudziak D, Kamphorst AO, Heidkamp GF et al. Differential antigen processing by dendritic cell subsets in vivo. Science 315(5808), 107-111 (2007).
64. Kasahara S, Clark EA. Dendritic cellassociated lectin 2 (DCAL2) defines a distinct CD8a-dendritic cell subset. J. Leukoc. Biol. 91(3), 437-448 (2011).
65. Yamazaki S, Dudziak D, Heidkamp GF et al. CD8+ CD205+ splenic dendritic cells are specialized to induce Foxp3+ regulatory T cells. J. Immunol. 181(10), 6923-6933 (2008).
66. Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature 449(7161), 419-426 (2007).
67. Dhodapkar MV, Steinman RM. Antigenbearing immature dendritic cells induce peptide-specific CD8+ regulatory T cells in vivo in humans. Blood 100(1), 174-177 (2002).
68. Dhodapkar MV, Steinman RM, Krasovsky J, Munz C, Bhardwaj N. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J. Exp. Med. 193(2), 233-238 (2001).
69. Chitta S, Santambrogio L, Stern LJ. GMCSF in the absence of other cytokines sustains human dendritic cell precursors with T cell regulatory activity and capacity to differentiate into functional dendritic cells. Immunol. Lett. 116(1), 41-54 (2008).
70. Gregori S, Tomasoni D, Pacciani V et al. Differentiation of Type 1 T regulatory cells (Tr1) by tolerogenic DC-10 requires the IL-10-dependent ILT4/HLA-G pathway. Blood 116(6), 935-944 (2010).
71. Anderson A, Martens CL, Hendrix R et al. Expanded nonhuman primate tregs exhibit a unique gene expression signature and potently downregulate alloimmune responses. Am. J. Transplant. 8(11), 2252-2264 (2008).
72. Anderson AE, Swan DJ, Sayers BL et al. LPS activation is required for migratory activity and antigen presentation by tolerogenic dendritic cells. J. Leukoc. Biol. 85(2), 243-250 (2009).
73. Giannoukakis N, Bonham CA, Qian S et al. Prolongation of cardiac allograft survival using dendritic cells treated with NF-kB decoy oligodeoxyribonucleotides. Mol. Ther. 1(5 Pt 1), 430-437 (2000).
74. Harry RA, Anderson AE, Isaacs JD, Hilkens CM. Generation and characterisation of therapeutic tolerogenic dendritic cells for rheumatoid arthritis. Ann. Rheum. Dis 69(11), 2042-2050 (2010).
75. Mauri C, Bosma A. Immune regulatory function of B cells. Annu. Rev. Immunol. 30, 221-241 (2012).
76. Mauri C, Ehrenstein MR. The 'short' history of regulatory B cells. Trends Immunol. 29(1), 34-40 (2008).
77. Bouaziz JD, Le Buanec H, Saussine A, Bensussan A, Bagot M. IL-10 producing regulatory B cells in mice and humans: State of the art. Curr. Mol. Med. 12(5), 519-527 (2012).
78. Dilillo DJ, Matsushita T, Tedder TF. B10 cells and regulatory B cells balance immune responses during inflammation, autoimmunity, and cancer. Ann. NY Acad. Sci. 1183, 38-57 (2010).
79. Matsushita T, Tedder TF. Identifying regulatory B cells (B10 cells) that produce IL-10 in mice. Methods Mol. Biol. 677, 99-111 (2011).
80. Shultz LD, Ishikawa F, Greiner DL. Humanized mice in translational biomedical research. Nat. Rev. Immunol. 7(2), 118-130 (2007).
81. Zahorchak AF, Kean LS, Tokita D et al. Infusion of stably immature monocyte-derived dendritic cells plus CTLA4Ig modulates alloimmune reactivity in rhesus macaques. Transplantation 84(2), 196-206 (2007).
82. Sordi V, Bianchi G, Buracchi C et al. Differential effects of immunosuppressive drugs on chemokine receptor CCR7 in human monocyte-derived dendritic cells: Selective upregulation by rapamycin. Transplantation 82(6), 826-834 (2006).
83. Karnes RJ, Whelan CM, Kwon ED. Immunotherapy for prostate cancer. Curr. Pharm. Des. 12(7), 807-817 (2006).
84. Kikuchi T. Genetically modified dendritic cells for therapeutic immunity. Tohoku J. Exp. Med. 208(1), 1-8 (2006).
85. Pinzon-Charry A, Schmidt C, Lopez JA. Dendritic cell immunotherapy for breast cancer. Expert Opin Biol Ther. 6(6), 591-604 (2006).
86. Riker AI, Jove R, Daud AI. Immunotherapy as part of a multidisciplinary approach to melanoma treatment. Front. Biosci. 11, 1-14 (2006).
87. Saito H, Frleta D, Dubsky P, Palucka AK. Dendritic cell-based vaccination against cancer. Hematol. Oncol. Clin. North Am. 20(3), 689-710 (2006).
88. Xia D, Moyana T, Xiang J. Combinational adenovirus-mediated gene therapy and dendritic cell vaccine in combating well-established tumors. Cell Res. 16(3), 241-259 (2006).
89. Butterfield LH, Ribas A, Dissette VB et al. A Phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alphafetoprotein peptides. Clin. Cancer Res. 12(9), 2817-2825 (2006).
90. Dillman R, Selvan S, Schiltz P et al. Phase I/II trial of melanoma patient-specific vaccine of proliferating autologous tumor cells, dendritic cells, and GM-CSF: planned interim analysis. Cancer Biother. Radiopharm. 19(5), 658-665 (2004).
91. Hersey P, Menzies SW, Halliday GM et al. Phase I/II study of treatment with dendritic cell vaccines in patients with disseminated melanoma. Cancer Immunol. Immunother. 53(2), 125-134 (2004).
92. Kyte JA, Mu L, Aamdal S et al. Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA. Cancer Gene Ther. 13(10), 905-918 (2006).
93. Lodge PA, Jones LA, Bader RA, Murphy GP, Salgaller ML. Dendritic cell-based immunotherapy of prostate cancer: Immune monitoring of a Phase II clinical trial. Cancer Res. 60(4), 829-833 (2000).
94. Lou E, Marshall J, Aklilu M, Cole D, Chang D, Morse M. A Phase II study of active immunotherapy with PANVAC or autologous, cultured dendritic cells infected with PANVAC after complete resection of hepatic metastases of colorectal carcinoma. Clin. Colorectal Cancer 5(5), 368-371 (2006).
95. Marten A, Flieger D, Renoth S et al. Therapeutic vaccination against metastatic renal cell carcinoma by autologous dendritic cells: preclinical results and outcome of a first clinical Phase I/II trial. Cancer Immunol. Immunother. 51(11-12), 637-644 (2002).
96. Morse MA, Nair SK, Boczkowski D et al. The feasibility and safety of immunotherapy with dendritic cells loaded with CEA mRNA following neoadjuvant chemoradiotherapy and resection of pancreatic cancer. Int. J. Gastrointest. Cancer 32(1), 1-6 (2002).
97. O'Rourke MG, Johnson M, Lanagan C et al. Durable complete clinical responses in a Phase I/II trial using an autologous melanoma cell/dendritic cell vaccine. Cancer Immunol. Immunother. 52(6), 387-395 (2003).
98. Slingluff CL Jr, Petroni GR, Yamshchikov GV et al. Clinical and immunologic results of a randomized Phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colonystimulating factor in adjuvant or pulsed on dendritic cells. J. Clin. Oncol. 21(21), 4016-4026 (2003).
99. Tjoa BA, Simmons SJ, Bowes VA et al. Evaluation of Phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides. Prostate 36(1), 39-44 (1998).
100. Tjoa BA, Simmons SJ, Elgamal A et al. Follow-up evaluation of a Phase II prostate cancer vaccine trial. Prostate 40(2), 125-129 (1999).
101. Weihrauch MR, Ansen S, Jurkiewicz E et al. Phase I/II combined chemoimmunotherapy with carcinoembryonic antigen-derived HLA-A2-restricted CAP-1 peptide and irinotecan, 5-fluorouracil, and leucovorin in patients with primary metastatic colorectal cancer. Clin. Cancer Res. 11(16), 5993-6001 (2005).
102. Yamanaka R, Abe T, Yajima N et al. Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: Results of a clinical Phase I/ II trial. Br. J. Cancer 89(7), 1172-1179 (2003).
103. Yamanaka R, Homma J, Yajima N et al. Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: Results of a clinical Phase I/II trial. Clin. Cancer Res. 11(11), 4160-4167 (2005).
104. Lu L, Gambotto A, Lee WC et al. Adenoviral delivery of CTLA4Ig into myeloid dendritic cells promotes their in vitro tolerogenicity and survival in allogeneic recipients. Gene Ther. 6(4), 554-563 (1999).
105. Feili-Hariri M, Falkner DH, Gambotto A et al. Dendritic cells transduced to express interleukin-4 prevent diabetes in nonobese diabetic mice with advanced insulitis. Hum. Gene Ther. 14(1), 13-23 (2003).
106. Ruffner MA, Robbins PD. Dendritic cells transduced to express interleukin 4 reduce diabetes onset in both normoglycemic and prediabetic nonobese diabetic mice. PLoS ONE 5(7), e11848 (2010).
107. Henry E, Desmet CJ, Garze V et al. Dendritic cells genetically engineered to express IL-10 induce long-lasting antigen-specific tolerance in experimental asthma. J. Immunol. 181(10), 7230-7242 (2008).
108. Torisu M, Murakami H, Akbar F et al. Protective role of interleukin-10-producing regulatory dendritic cells against murine autoimmune gastritis. J. Gastroenterol. 43(2), 100-107 (2008).
109. Coates PT, Krishnan R, Kireta S, Johnston J, Russ GR. Human myeloid dendritic cells transduced with an adenoviral interleukin-10 gene construct inhibit human skin graft rejection in humanized NOD-SCID chimeric mice. Gene Ther. 8(16), 1224-1233 (2001).
110. Takayama T, Nishioka Y, Lu L, Lotze MT, Tahara H, Thomson AW. Retroviral delivery of viral interleukin-10 into myeloid dendritic cells markedly inhibits their allostimulatory activity and promotes the induction of T-cell hyporesponsiveness. Transplantation 66(12), 1567-1574 (1998).
111. O'Rourke RW, Kang SM, Lower JA et al. A dendritic cell line genetically modified to express CTLA4-IG as a means to prolong islet allograft survival. Transplantation 69(7), 1440-1446 (2000).
112. Takayama T, Morelli AE, Robbins PD, Tahara H, Thomson AW. Feasibility of CTLA4Ig gene delivery and expression in vivo using retrovirally transduced myeloid dendritic cells that induce alloantigen-specific T cell anergy in vitro. Gene Ther. 7(15), 1265-1273 (2000).
113. Bonham CA, Peng L, Liang X et al. Marked prolongation of cardiac allograft survival by dendritic cells genetically engineered with NF kappa B oligodeoxyribonucleotide decoys and adenoviral vectors encoding CTLA4-Ig. J. Immunol. 169(6), 3382-3391 (2002).
114. Mellor AL, Munn DH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat. Rev. Immunol. 4(10), 762-774 (2004).
115. Terness P, Bauer TM, Rose L et al. Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: Mediation of suppression by tryptophan metabolites. J. Exp. Med. 196(4), 447-457 (2002).
116. An XJ, Bai CX, Xia JB et al. Immature dendritic cells expressing indoleamine 2,3-dioxygenase suppress ovalbumin-induced allergic airway inflammation in mice. J. Investig. Allergol. Clin. Immunol. 21(3), 185-192 (2011).
117. Min WP, Gorczynski R, Huang XY et al. Dendritic cells genetically engineered to express Fas ligand induce donor-specific hyporesponsiveness and prolong allograft survival. J. Immunol. 164(1), 161-167 (2000).
118. Luo X, Tarbell KV, Yang H et al. Dendritic cells with TGF-beta1 differentiate naive CD4+CD25- T cells into islet-protective Foxp3+ regulatory T cells. Proc. Natl Acad. Sci. USA 104(8), 2821-2826 (2007).
119. Gorczynski RM, Bransom J, Cattral M et al. Synergy in induction of increased renal allograft survival after portal vein infusion of dendritic cells transduced to express TGFbeta and IL-10, along with administration of CHO cells expressing the regulatory molecule OX-2. Clin. Immunol. 95(3), 182-189 (2000).
120. Hernandez A, Burger M, Blomberg BB et al. Inhibition of NF-kappaB during human dendritic cell differentiation generates anergy and regulatory T-cell activity for one but not two human leukocyte antigen DR mismatches. Hum. Immunol. 68(9), 715-729 (2007).
121. Adorini L, Penna G. Induction of tolerogenic dendritic cells by vitamin D receptor agonists. Handbook Exp. Pharmacol. (188), 251-273 (2009).
122. Adorini L. Tolerogenic dendritic cells induced by vitamin D receptor ligands enhance regulatory T cells inhibiting autoimmune diabetes. Ann. NY Acad. Sci. 987, 258-261 (2003).
123. Gregori S, Casorati M, Amuchastegui S, Smiroldo S, Davalli AM, Adorini L. Regulatory T cells induced by 1alpha, 25-dihydroxyvitamin D3 and mycophenolate mofetil treatment mediate transplantation tolerance. J. Immunol. 167(4), 1945-1953 (2001).
124. Griffin MD, Lutz W, Phan VA, Bachman LA, McKean DJ, Kumar R. Dendritic cell modulation by 1alpha, 25 dihydroxyvitamin D3 and its analogs: A vitamin D receptordependent pathway that promotes a persistent state of immaturity in vitro and in vivo. Proc. Natl Acad. Sci. USA 98(12), 6800-6805 (2001).
125. Penna G, Adorini L. 1alpha, 25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J. Immunol. 164(5), 2405-2411 (2000).
126. Lee JI, Ganster RW, Geller DA, Burckart GJ, Thomson AW, Lu L Cyclosporine A inhibits the expression of costimulatory molecules on in vitro-generated dendritic cells: Association with reduced nuclear translocation of nuclear factor kappa B. Transplantation 68(9), 1255-1263 (1999).
127. Abe M, Thomson AW. Influence of immunosuppressive drugs on dendritic cells. Transpl. Immunol. 11(3-4), 357-365 (2003).
128. Hackstein H, Taner T, Zahorchak AF et al. Rapamycin inhibits IL-4-induced dendritic cell maturation in vitro and dendritic cell mobilization and function in vivo. Blood 101(11), 4457-4463 (2003).
129. Thomas JM, Contreras JL, Jiang XL et al. Peritransplant tolerance induction in macaques: early events reflecting the unique synergy between immunotoxin and deoxyspergualin. Transplantation 68(11), 1660-1673 (1999).
130. Mehling A, Grabbe S, Voskort M, Schwarz T, Luger TA, Beissert S. Mycophenolate mofetil impairs the maturation and function of murine dendritic cells. J. Immunol. 165(5), 2374-2381 (2000). (Pubitemid 36976054)